Loading organizations...
Key people at Swiss Federal Office of Public Health.
The Swiss Federal Office of Public Health (FOPH) implements a comprehensive Health Technology Assessment (HTA) process. It produces detailed HTA reports, evaluating medical technologies for effectiveness, appropriateness, and cost-effectiveness. This rigorous methodology guides healthcare policy decisions, ensuring quality and utility of public health interventions across Switzerland.
The FOPH's HTA engagement originated from practical experience within the Swiss Federal Office of Social Security during the 1980s. This fostered international involvement, making Switzerland a founding partner of EUnetHTA in 2009 and a foundational INAHTA member. A dedicated HTA unit was established in 2017 for report production and re-evaluation programs.
Serving Swiss policymakers and its population, the FOPH ensures all reimbursed medical technologies meet stringent criteria. Its mission is to continuously improve public health by guaranteeing adoption of beneficial advancements, while preventing ineffective or uneconomical solutions. The office commits to leveraging evidence for the nation’s sustained well-being.
Key people at Swiss Federal Office of Public Health.
Swiss Federal Office of Public Health has 1 tracked investment across 1 company. The latest tracked deal is $25.0M Series B in Memo Therapeutics in February 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 1, 2022 | Memo Therapeutics | $25.0M Series B | Swisscanto Invest, Swiss Federal Office OF Public Health | Adjuvant Capital, Kurma Partners, Pureos Bioventures, Andreas Wüpper, GF Group, Verve Ventures, Christian Schneider, Zürcher Kantonalbank |